Neuroinformation PD Review References: 2004
 

Navigation:

Home
Up
About this Site
Advanced Search
Feedback
Links
News
Site Map
3D model of DHA

Back to: References Section

PD Review References for 2004:

Abad, V. C. and C. Guilleminault (2004). "Review of rapid eye movement behavior sleep disorders." Curr Neurol Neurosci Rep 4(2): 157-63.

Agorogiannis, E. I., G. I. Agorogiannis, et al. (2004). "Protein misfolding in neurodegenerative diseases." Neuropathol Appl Neurobiol 30(3): 215-24.

Alexopoulos, G. S., J. Streim, et al. (2004). "Using antipsychotic agents in older patients." J Clin Psychiatry 65 Suppl 2: 5-99; discussion 100-102; quiz 103-4.

Alm, P. A. (2004). "Stuttering and the basal ganglia circuits: a critical review of possible relations." J Commun Disord 37(4): 325-69.

Ando, K. (2004). "[Neuropsychopharmacological profile of nicotine]." Nihon Shinkei Seishin Yakurigaku Zasshi 24(2): 55-9.

Ariga, H. (2004). "[Function of DJ]-1, a causative gene for familial Parkinson's disease]." Seikagaku 76(5): 456-9.

Asanuma, M., I. Miyazaki, et al. (2004). "Neuroprotective effects of nonsteroidal anti-inflammatory drugs on neurodegenerative diseases." Curr Pharm Des 10(6): 695-700.

Ashkan, K., B. Wallace, et al. (2004). "Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on?" Br J Neurosurg 18(1): 19-34.

Ballard, C. G. (2004). "Definition and diagnosis of dementia with Lewy bodies." Dement Geriatr Cogn Disord 17 Suppl 1: 15-24.

Baptista, M. J., M. R. Cookson, et al. (2004). "Parkin and alpha-synuclein: opponent actions in the pathogenesis of Parkinson's disease." Neuroscientist 10(1): 63-72.

Barcia, C., M. E. Emborg, et al. (2004). "Blood vessels and parkinsonism." Front Biosci 9: 277-82.

Barcia Gonzalez, C. and M. T. Herrero Ezquerro (2004). "[Inflammation and Parkinson's disease]." Rev Neurol 38(6): 545-53.

Barker, R. A. and T. Foltynie (2004). "The future challenges in Parkinson's disease." J Neurol 251(3): 361-5.

Barnham, K. J., C. L. Masters, et al. (2004). "Neurodegenerative diseases and oxidative stress." Nat Rev Drug Discov 3(3): 205-14.

Baskys, A. (2004). "Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms." J Clin Psychiatry 65 Suppl 11: 16-22.

Bertoli-Avella, A. M., B. A. Oostra, et al. (2004). "Chasing genes in Alzheimer's and Parkinson's disease." Hum Genet 114(5): 413-38.

Bertolin Guillen, J. M., C. Saez Abad, et al. (2004). "[Efficacy of electroconvulsive therapy: a systematic review of scientific evidences]." Actas Esp Psiquiatr 32(3): 153-65.

Blake, A. D., A. C. Badway, et al. (2004). "Delineating somatostatin's neuronal actions." Curr Drug Targets CNS Neurol Disord 3(2): 153-60.

Boje, K. M. (2004). "Nitric oxide neurotoxicity in neurodegenerative diseases." Front Biosci 9: 763-76.

Bonifati, V., B. A. Oostra, et al. (2004). "Unraveling the pathogenesis of Parkinson's disease--the contribution of monogenic forms." Cell Mol Life Sci 61(14): 1729-50.

Bosboom, J. L. and E. Wolters (2004). "Psychotic symptoms in Parkinson's disease: pathophysiology and management." Expert Opin Drug Saf 3(3): 209-20.

Bossy-Wetzel, E., R. Schwarzenbacher, et al. (2004). "Molecular pathways to neurodegeneration." Nat Med 10 Suppl: S2-9.

Bowron, A. (2004). "Practical considerations in the use of apomorphine injectable." Neurology 62(6 Suppl 4): S32-6.

Brooks, D. J. (2004). "Safety and tolerability of COMT inhibitors." Neurology 62(1 Suppl 1): S39-46.

Brotini, S. and G. L. Gigli (2004). "Epidemiology and clinical features of sleep disorders in extrapyramidal disease." Sleep Med 5(2): 169-79.

Brusa, A., R. Stoehr, et al. (2004). "Progressive supranuclear palsy: new disease or variant of postencephalitic parkinsonism?" Mov Disord 19(3): 247-52.

Bryant, P. R., C. C. Geis, et al. (2004). "Stroke and neurodegenerative disorders. 4. Neurodegenerative disorders." Arch Phys Med Rehabil 85(3 Suppl 1): S21-33.

Burke, R. E. (2004). "Recent advances in research on Parkinson disease: synuclein and parkin." Neurologist 10(2): 75-81.

Burke, W. J., S. W. Li, et al. (2004). "Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases." Neurotoxicology 25(1-2): 101-15.

Burton, D. A., G. Nicholson, et al. (2004). "Anaesthesia in elderly patients with neurodegenerative disorders: special considerations." Drugs Aging 21(4): 229-42.

Camicioli, R. and N. Fisher (2004). "Progress in clinical neurosciences: Parkinson's disease with dementia and dementia with Lewy bodies." Can J Neurol Sci 31(1): 7-21.

Carini, M., G. Aldini, et al. (2004). "Mass spectrometry for detection of 4-hydroxy-trans-2-nonenal (HNE) adducts with peptides and proteins." Mass Spectrom Rev 23(4): 281-305.

Carreras, M. C., M. C. Franco, et al. (2004). "Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease." Mol Aspects Med 25(1-2): 125-39.

Castagnoli, K. and T. Murugesan (2004). "Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links?" Neurotoxicology 25(1-2): 279-91.

Chan, D. K., D. Cordato, et al. (2004). "Comparison of environmental and genetic factors for Parkinson's disease between Chinese and Caucasians." Neuroepidemiology 23(1-2): 13-22.

Chekhonin, V. P., V. P. Baklaushev, et al. (2004). "[Modeling Parkinson's disease and objectifying the nigro-striatum system dysfunction]." Zh Nevrol Psikhiatr Im S S Korsakova 104(1): 59-68.

Chen, L. W., K. K. Yung, et al. (2004). "Neurokinin peptides and neurokinin receptors as potential therapeutic intervention targets of basal ganglia in the prevention and treatment of Parkinson's disease." Curr Drug Targets 5(2): 197-206.

Cheng, E. M., A. Siderowf, et al. (2004). "Development of quality of care indicators for Parkinson's disease." Mov Disord 19(2): 136-50.

Ciubotaru, V., Y. Poinsignon, et al. (2004). "[Severe pleuropericarditis induced by long-term bromocriptin therapy, report of a case and review of the literature]." Rev Med Interne 25(4): 310-4.

Clarke, C. E. (2004). "Neuroprotection and pharmacotherapy for motor symptoms in Parkinson's disease." Lancet Neurol 3(8): 466-74.

Collins, S. J., V. A. Lawson, et al. (2004). "Transmissible spongiform encephalopathies." Lancet 363(9402): 51-61.

Craft, S. and G. S. Watson (2004). "Insulin and neurodegenerative disease: shared and specific mechanisms." Lancet Neurol 3(3): 169-78.

de la Fuente-Fernandez, R. and A. J. Stoessl (2004). "The biochemical bases of the placebo effect." Sci Eng Ethics 10(1): 143-50.

Defebvre, L. (2004). "[Motor complications in dopa treatment of parkinson disease: clinical description and evaluation]." Therapie 59(1): 93-6.

Dewey, R. B., Jr. (2004). "Management of motor complications in Parkinson's disease." Neurology 62(6 Suppl 4): S3-7.

Dlamini, Z., Z. Mbita, et al. (2004). "Genealogy, expression, and molecular mechanisms in apoptosis." Pharmacol Ther 101(1): 1-15.

Dobson, A. W., K. M. Erikson, et al. (2004). "Manganese neurotoxicity." Ann N Y Acad Sci 1012: 115-28.

Dobson, J. (2004). "Magnetic iron compounds in neurological disorders." Ann N Y Acad Sci 1012: 183-92.

Dogrukol-Ak, D., F. Tore, et al. (2004). "Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects." Curr Pharm Des 10(12): 1325-40.

Doraiswamy, P. M. and A. E. Finefrock (2004). "Metals in our minds: therapeutic implications for neurodegenerative disorders." Lancet Neurol 3(7): 431-4.

Drucker-Colin, R. and L. Verdugo-Diaz (2004). "Cell transplantation for Parkinson's disease: present status." Cell Mol Neurobiol 24(3): 301-16.

Duda, J. E. (2004). "Pathology and neurotransmitter abnormalities of dementia with Lewy bodies." Dement Geriatr Cogn Disord 17 Suppl 1: 3-14.

Eckert, T. and D. Eidelberg (2004). "The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson's disease and multiple system atrophy." Clin Auton Res 14(2): 84-91.

Ekshyyan, O. and T. Y. Aw (2004). "Apoptosis in acute and chronic neurological disorders." Front Biosci 9: 1567-76.

Factor, S. A. (2004). "Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease." Neurology 62(6 Suppl 4): S12-7.

Fendyur, A., I. Kaiserman, et al. (2004). "The burst of mitochondrial diseases: neurons and calcium." Isr Med Assoc J 6(6): 356-9.

Fernandez-Espejo, E. (2004). "Pathogenesis of Parkinson's disease: prospects of neuroprotective and restorative therapies." Mol Neurobiol 29(1): 15-30.

Finley, J. W. (2004). "Does environmental exposure to manganese pose a health risk to healthy adults?" Nutr Rev 62(4): 148-53.

Fisone, G., A. Borgkvist, et al. (2004). "Caffeine as a psychomotor stimulant: mechanism of action." Cell Mol Life Sci 61(7-8): 857-72.

Fiszer, U. (2004). "[Selected aspects of immunological disorders in Parkinson disease]." Neurol Neurochir Pol 38(1 Suppl 1): S63-6.

Fraix, V. (2004). "[Gene therapy for Parkinson's disease]." Rev Med Interne 25(7): 524-7.

Fraix, V., P. Pollak, et al. (2004). "[Deep brain stimulation]." Rev Neurol (Paris) 160(5 Pt 1): 511-21.

Friedman, J. H. and K. L. Chou (2004). "Sleep and fatigue in Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S27-35.

Frucht, S. J. (2004). "Movement disorder emergencies in the perioperative period." Neurol Clin 22(2): 379-87.

Galvez-Jimenez, N. and A. E. Lang (2004). "The perioperative management of Parkinson's disease revisited." Neurol Clin 22(2): 367-77.

Gekht, A. B. (2004). "[Treatment of Parkinson's disease: use of piribedil]." Zh Nevrol Psikhiatr Im S S Korsakova 104(1): 54-6.

Giroud Benitez, J. L. (2004). "[Early-onset Parkinson's disease]." Rev Neurol 38(7): 698-9.

Glanzer, J. G., P. G. Haydon, et al. (2004). "Expression profile analysis of neurodegenerative disease: advances in specificity and resolution." Neurochem Res 29(6): 1161-8.

Gotz, M. E., K. Double, et al. (2004). "The relevance of iron in the pathogenesis of Parkinson's disease." Ann N Y Acad Sci 1012: 193-208.

Grunblatt, E. (2004). "The benefits of microarrays as tools for studying neuropsychiatric disorders." Drugs Today (Barc) 40(2): 147-56.

Gupta, A. K. and R. Bluhm (2004). "Seborrheic dermatitis." J Eur Acad Dermatol Venereol 18(1): 13-26; quiz 19-20.

Halberstadt, C., D. F. Emerich, et al. (2004). "Use of Sertoli cell transplants to provide local immunoprotection for tissue grafts." Expert Opin Biol Ther 4(6): 813-25.

HaMai, D. and S. C. Bondy (2004). "Oxidative basis of manganese neurotoxicity." Ann N Y Acad Sci 1012: 129-41.

Hamani, C., J. A. Saint-Cyr, et al. (2004). "The subthalamic nucleus in the context of movement disorders." Brain 127(Pt 1): 4-20.

Harrower, T. P. and R. A. Barker (2004). "Is there a future for neural transplantation?" BioDrugs 18(3): 141-53.

Harrower, T. P. and R. A. Barker (2004). "The emerging technologies of neural xenografting and stem cell transplantation for treating neurodegenerative disorders." Drugs Today (Barc) 40(2): 171-89.

Hashimoto, T. (2004). "[Microrecording: a guide to stereotactic brain operations]." No Shinkei Geka 32(3): 297-303.

Hattori, N. and Y. Mizuno (2004). "Pathogenetic mechanisms of parkin in Parkinson's disease." Lancet 364(9435): 722-4.

Heales, S. J., A. A. Lam, et al. (2004). "Neurodegeneration or neuroprotection: the pivotal role of astrocytes." Neurochem Res 29(3): 513-9.

Heiss, W. D. and R. Hilker (2004). "The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease." Eur J Neurol 11(1): 5-12.

Hening, W. A., R. P. Allen, et al. (2004). "An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder." Sleep 27(3): 560-83.

Hermann, A., M. Gerlach, et al. (2004). "Neurorestoration in Parkinson's disease by cell replacement and endogenous regeneration." Expert Opin Biol Ther 4(2): 131-43.

Hogg, R. C. and D. Bertrand (2004). "Nicotinic acetylcholine receptors as drug targets." Curr Drug Targets CNS Neurol Disord 3(2): 123-30.

Ikemoto, K. (2004). "Significance of human striatal D-neurons: implications in neuropsychiatric functions." Prog Neuropsychopharmacol Biol Psychiatry 28(3): 429-34.

Imai, Y. and R. Takahashi (2004). "[Dopaminergic neuronal death in Parkinson's disease: is accumulation of unfolded proteins a cause or effect?]." Tanpakushitsu Kakusan Koso 49(7 Suppl): 1113-7.

Ismail, M. S. and I. H. Richard (2004). "A reality test: How well do we understand psychosis in Parkinson's disease?" J Neuropsychiatry Clin Neurosci 16(1): 8-18.

Jayakar, S. S. and M. Dikshit (2004). "AMPA receptor regulation mechanisms: future target for safer neuroprotective drugs." Int J Neurosci 114(6): 695-734.

Jenner, P. (2004). "Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation." Neurology 62(1 Suppl 1): S47-55.

Kalia, S. K., J. E. Nash, et al. (2004). "To serve and protect? Interventions in the subthalamic nucleus for Parkinson's disease. Commentary on "Ablation of the subthalamic nucleus protects dopaminergic phenotype but not cell survival in a rat model of Parkinson's disease"." Exp Neurol 185(2): 201-3.

Kang, G. A. and J. M. Bronstein (2004). "Psychosis in nursing home patients with Parkinson's disease." J Am Med Dir Assoc 5(3): 167-73.

Kim, D. W. (2004). "Efficient induction of dopaminergic neurons from embryonic stem cells for application to Parkinson's disease." Yonsei Med J 45 Suppl: 23-7.

Kim, S., J. H. Seo, et al. (2004). "Alpha-synuclein, Parkinson's disease, and Alzheimer's disease." Parkinsonism Relat Disord 10 Suppl 1: S9-13.

Kim, S. I., H. Voshol, et al. (2004). "Neuroproteomics: expression profiling of the brain's proteomes in health and disease." Neurochem Res 29(6): 1317-31.

Kinkead, B. and C. B. Nemeroff (2004). "Neurotensin, schizophrenia, and antipsychotic drug action." Int Rev Neurobiol 59: 327-49.

Kirik, D., B. Georgievska, et al. (2004). "Localized striatal delivery of GDNF as a treatment for Parkinson disease." Nat Neurosci 7(2): 105-10.

Kohno, Y. and S. Takeuchi (2004). "[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole]." Nippon Yakurigaku Zasshi 123(6): 429-40.

Koller, W. and M. Stacy (2004). "Other formulations and future considerations for apomorphine for subcutaneous injection therapy." Neurology 62(6 Suppl 4): S22-6.

Koller, W. C. and W. Tse (2004). "Unmet medical needs in Parkinson's disease." Neurology 62(1 Suppl 1): S1-8.

Kondo, T. (2004). "[Parkinson's disease, familial Parkinson's disease]." Nippon Rinsho 62 Suppl: 97-101.

Kostic, V. S. (2004). "Comt inhibition in the treatment of Parkinson's disease: neuroprotection and future perspectives." Adv Exp Med Biol 541: 75-90.

Kuzuhara, S. (2004). "[Clinical features of Parkinson's disease in the elderly]." Nippon Ronen Igakkai Zasshi 41(3): 245-53.

Lang, A. E. and J. A. Obeso (2004). "Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough." Lancet Neurol 3(5): 309-16.

Lansbury, P. T., Jr. (2004). "Back to the future: the 'old-fashioned' way to new medications for neurodegeneration." Nat Med 10 Suppl: S51-7.

Le, W. and S. H. Appel (2004). "Mutant genes responsible for Parkinson's disease." Curr Opin Pharmacol 4(1): 79-84.

Leon, J., D. Acuna-Castroviejo, et al. (2004). "Melatonin and mitochondrial function." Life Sci 75(7): 765-90.

LeWitt, P. A. (2004). "Subcutaneously administered apomorphine: pharmacokinetics and metabolism." Neurology 62(6 Suppl 4): S8-11.

LeWitt, P. A. and D. Nyholm (2004). "New developments in levodopa therapy." Neurology 62(1 Suppl 1): S9-16.

Linazaroso, G., N. van Blercom, et al. (2004). "[Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa]." Neurologia 19(3): 117-27.

Lindvall, O., Z. Kokaia, et al. (2004). "Stem cell therapy for human neurodegenerative disorders-how to make it work." Nat Med 10 Suppl: S42-50.

Linnebur, S. A. (2004). "What's new about old drugs." J Gerontol Nurs 30(1): 4-11.

Low, S. J. and C. L. Roland (2004). "Review of NMDA antagonist-induced neurotoxicity and implications for clinical development." Int J Clin Pharmacol Ther 42(1): 1-14.

Lozano, A. M. and N. Mahant (2004). "Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences." Parkinsonism Relat Disord 10 Suppl 1: S49-57.

Lu, Y. (2004). "Recombinant adeno-associated virus as delivery vector for gene therapy--a review." Stem Cells Dev 13(1): 133-45.

Luque, J. M. and M. Gimenez y Ribotta (2004). "Neural stem cells and the quest for restorative neurology." Histol Histopathol 19(1): 271-80.

Magyar, K. and B. Szende (2004). "(-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties." Neurotoxicology 25(1-2): 233-42.

Marien, M. R., F. C. Colpaert, et al. (2004). "Noradrenergic mechanisms in neurodegenerative diseases: a theory." Brain Res Brain Res Rev 45(1): 38-78.

Marin, I., J. I. Lucas, et al. (2004). "Parkin and relatives: the RBR family of ubiquitin ligases." Physiol Genomics 17(3): 253-63.

Marino, G. and C. Lopez-Otin (2004). "Autophagy: molecular mechanisms, physiological functions and relevance in human pathology." Cell Mol Life Sci 61(12): 1439-54.

Marshall, V. L. and D. G. Grosset (2004). "GPI-1485 (Guilford)." Curr Opin Investig Drugs 5(1): 107-12.

Marzolini, C., E. Paus, et al. (2004). "Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance." Clin Pharmacol Ther 75(1): 13-33.

Mattson, M. P. (2004). "Metal-catalyzed disruption of membrane protein and lipid signaling in the pathogenesis of neurodegenerative disorders." Ann N Y Acad Sci 1012: 37-50.

McClure, S. M., M. K. York, et al. (2004). "The neural substrates of reward processing in humans: the modern role of FMRI." Neuroscientist 10(3): 260-8.

McGeer, P. L. and E. G. McGeer (2004). "Inflammation and neurodegeneration in Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S3-7.

McInerney-Leo, A., K. Gwinn-Hardy, et al. (2004). "Prevalence of Parkinson's disease in populations of African ancestry: a review." J Natl Med Assoc 96(7): 974-9.

McIntyre, C. C., M. Savasta, et al. (2004). "How does deep brain stimulation work? Present understanding and future questions." J Clin Neurophysiol 21(1): 40-50.

McKeith, I., J. Mintzer, et al. (2004). "Dementia with Lewy bodies." Lancet Neurol 3(1): 19-28.

McKeith, I. G. and U. P. Mosimann (2004). "Dementia with Lewy bodies and Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S15-8.

Meissner, W., M. P. Hill, et al. (2004). "Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials." Trends Pharmacol Sci 25(5): 249-53.

Meredith, G. E., G. M. Halliday, et al. (2004). "A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation." Parkinsonism Relat Disord 10(4): 191-202.

Miller, F. G. (2004). "Sham surgery: an ethical analysis." Sci Eng Ethics 10(1): 157-66.

Minagar, A. and R. E. Kelley (2004). "Movement disorders." Prim Care 31(1): 111-27.

Montgomery, E. B., Jr. (2004). "Rehabilitative approaches to Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S43-7.

Montine, K. S., J. F. Quinn, et al. (2004). "Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases." Chem Phys Lipids 128(1-2): 117-24.

Moos, T. and E. H. Morgan (2004). "The metabolism of neuronal iron and its pathogenic role in neurological disease: review." Ann N Y Acad Sci 1012: 14-26.

Moran, L. B. and M. B. Graeber (2004). "The facial nerve axotomy model." Brain Res Brain Res Rev 44(2-3): 154-78.

Murakami, N. (2004). "[Parkinsonism-dementia complex on Guam]." Nippon Rinsho 62 Suppl: 118-21.

Murata, M. (2004). "Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease." Curr Pharm Des 10(6): 687-93.

Nagata, K. (2004). "[Cigarette smoking and neurological disease]." No To Shinkei 56(3): 205-23.

Nagatsu, T. (2004). "Progress in monoamine oxidase (MAO) research in relation to genetic engineering." Neurotoxicology 25(1-2): 11-20.

Naoi, M., W. Maruyama, et al. (2004). "Dopamine-derived salsolinol derivatives as endogenous monoamine oxidase inhibitors: occurrence, metabolism and function in human brains." Neurotoxicology 25(1-2): 193-204.

Naumann, M. and W. Jost (2004). "Botulinum toxin treatment of secretory disorders." Mov Disord 19 Suppl 8: S137-41.

Nelson, R. L. (2004). "Epidemiology of fecal incontinence." Gastroenterology 126(1 Suppl 1): S3-7.

Newhouse, P., A. Singh, et al. (2004). "Nicotine and nicotinic receptor involvement in neuropsychiatric disorders." Curr Top Med Chem 4(3): 267-82.

Newhouse, P. A., A. Potter, et al. (2004). "Effects of nicotinic stimulation on cognitive performance." Curr Opin Pharmacol 4(1): 36-46.

Newman, M. B., C. D. Davis, et al. (2004). "Transplantation of human umbilical cord blood cells in the repair of CNS diseases." Expert Opin Biol Ther 4(2): 121-30.

Nguyen, N., V. Pradel, et al. (2004). "[Drug-induced parkinson syndromes]." Therapie 59(1): 105-12.

Nikolaus, S., M. Beu, et al. (2004). "The contribution of small animal positron emission tomography to the neurosciences--a critical evaluation." Rev Neurosci 15(2): 131-56.

Norris, E. H., B. I. Giasson, et al. (2004). "Alpha-synuclein: normal function and role in neurodegenerative diseases." Curr Top Dev Biol 60: 17-54.

Obeso, J. A., M. Rodriguez-Oroz, et al. (2004). "The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits." Neurology 62(1 Suppl 1): S17-30.

Ochiai, T., J. Regis, et al. (2004). "[Three dimensional stereotactic functional neurosurgical planning]." Nippon Rinsho 62(4): 669-76.

Okun, M. S. and J. L. Vitek (2004). "Lesion therapy for Parkinson's disease and other movement disorders: update and controversies." Mov Disord 19(4): 375-89.

Olanow, C. W. (2004). "Manganese-induced parkinsonism and Parkinson's disease." Ann N Y Acad Sci 1012: 209-23.

Olanow, C. W. (2004). "The scientific basis for the current treatment of Parkinson's disease." Annu Rev Med 55: 41-60.

Olanow, C. W., D. P. Perl, et al. (2004). "Lewy-body formation is an aggresome-related process: a hypothesis." Lancet Neurol 3(8): 496-503.

Olanow, C. W. and F. Stocchi (2004). "COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?" Neurology 62(1 Suppl 1): S72-81.

Oliveira, E., A. Michel, et al. (2004). "The pulmonary consultation in the perioperative management of patients with neurologic diseases." Neurol Clin 22(2): v, 277-91.

Ollinet, C., D. Bedague, et al. (2004). "[Functional surgery for movement disorders: implications for anaesthesia]." Ann Fr Anesth Reanim 23(4): 428-32.

O'Neill, M. J., D. Bleakman, et al. (2004). "AMPA receptor potentiators for the treatment of CNS disorders." Curr Drug Targets CNS Neurol Disord 3(3): 181-94.

Outeiro, T. F. and P. J. Muchowski (2004). "Molecular genetics approaches in yeast to study amyloid diseases." J Mol Neurosci 23(1-2): 49-60.

Ozelius, L. J. (2004). "Update on the genetics of primary torsion dystonia loci DYT6, DYT7, and DYT13 and the dystonia-plus locus DYT12." Adv Neurol 94: 109-12.

Paolini, M., A. Sapone, et al. (2004). "Parkinson's disease, pesticides and individual vulnerability." Trends Pharmacol Sci 25(3): 124-9.

Paviour, D. C., R. A. Surtees, et al. (2004). "Diagnostic considerations in juvenile parkinsonism." Mov Disord 19(2): 123-35.

Perez, R. G. and T. G. Hastings (2004). "Could a loss of alpha-synuclein function put dopaminergic neurons at risk?" J Neurochem 89(6): 1318-24.

Peschanski, M., A. C. Bachoud-Levi, et al. (2004). "Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease." Brain 127(Pt 6): 1219-28.

Pezzoli, G., M. Canesi, et al. (2004). "An overview of parkinsonian syndromes: data from the literature and from an Italian data-base." Sleep Med 5(2): 181-7.

Phillips, B. (2004). "Movement disorders: a sleep specialist's perspective." Neurology 62(5 Suppl 2): S9-16.

Piasecki, S. D. and J. W. Jefferson (2004). "Psychiatric complications of deep brain stimulation for Parkinson's disease." J Clin Psychiatry 65(6): 845-9.

Piccini, P. and A. Whone (2004). "Functional brain imaging in the differential diagnosis of Parkinson's disease." Lancet Neurol 3(5): 284-90.

Pirtosek, Z. and D. Flisar (2004). "Neuroprotection and dopamine agonists." Adv Exp Med Biol 541: 55-74.

Poewe, W. (2004). "The role of COMT inhibition in the treatment of Parkinson's disease." Neurology 62(1 Suppl 1): S31-8.

Pollak, P. (2004). "Movement disorders: Parkinson's disease dominates." Lancet Neurol 3(1): 15.

Przuntek, H., T. Muller, et al. (2004). "Diagnostic staging of Parkinson's disease: conceptual aspects." J Neural Transm 111(2): 201-16.

Rajendra, W., A. Armugam, et al. (2004). "Neuroprotection and peptide toxins." Brain Res Brain Res Rev 45(2): 125-41.

Recchia, A., P. Debetto, et al. (2004). "Alpha-synuclein and Parkinson's disease." Faseb J 18(6): 617-26.

Reniewska, B., M. Mulak, et al. (2004). "[Coexistence of Alzheimer's disease with pseudoexfoliation syndrome PEX]." Klin Oczna 106(1-2): 107-9.

Richardson, D. R. (2004). "Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions." Ann N Y Acad Sci 1012: 326-41.

Riederer, P., W. Danielczyk, et al. (2004). "Monoamine oxidase-B inhibition in Alzheimer's disease." Neurotoxicology 25(1-2): 271-7.

Ringheim, G. E. and K. Conant (2004). "Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections)." J Neuroimmunol 147(1-2): 43-9.

Rochet, J. C., T. F. Outeiro, et al. (2004). "Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease." J Mol Neurosci 23(1-2): 23-34.

Roig, R. L., G. M. Worsowicz, et al. (2004). "Geriatric rehabilitation. 3. Physical medicine and rehabilitation interventions for common disabling disorders." Arch Phys Med Rehabil 85(7 Suppl 3): S12-7; quiz S27-30.

Roitberg, B. (2004). "Transplantation for stroke." Neurol Res 26(3): 256-64.

Roitberg, B., K. Urbaniak, et al. (2004). "Cell transplantation for Parkinson's disease." Neurol Res 26(4): 355-62.

Ross, C. A. and M. A. Poirier (2004). "Protein aggregation and neurodegenerative disease." Nat Med 10 Suppl: S10-7.

Rossi, L., M. F. Lombardo, et al. (2004). "Mitochondrial dysfunction in neurodegenerative diseases associated with copper imbalance." Neurochem Res 29(3): 493-504.

Sachdev, P. (2004). "[Homocysteine and neuropsychiatric disorders]." Rev Bras Psiquiatr 26(1): 50-6.

Samii, A., J. G. Nutt, et al. (2004). "Parkinson's disease." Lancet 363(9423): 1783-93.

Sawabini, K. A. and R. L. Watts (2004). "Treatment of depression in Parkinson's disease." Parkinsonism Relat Disord 10 Suppl 1: S37-41.

Schapira, A. H. (2004). "Disease modification in Parkinson's disease." Lancet Neurol 3(6): 362-8.

Schapira, A. H. and C. W. Olanow (2004). "Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions." Jama 291(3): 358-64.

Scherzer, C. R. and M. B. Feany (2004). "Yeast genetics targets lipids in Parkinson's disease." Trends Genet 20(7): 273-7.

Schipper, H. M. (2004). "Heme oxygenase-1: transducer of pathological brain iron sequestration under oxidative stress." Ann N Y Acad Sci 1012: 84-93.

Sharma, S., M. Kheradpezhou, et al. (2004). "Neuroprotective actions of coenzyme Q10 in Parkinson's disease." Methods Enzymol 382: 488-509.

Shibasaki, H., H. Fukuyama, et al. (2004). "Neural control mechanisms for normal versus parkinsonian gait." Prog Brain Res 143: 199-205.

Shimazu, S. and I. Miklya (2004). "Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives." Prog Neuropsychopharmacol Biol Psychiatry 28(3): 421-7.

Sibon, I. and F. Tison (2004). "Vascular parkinsonism." Curr Opin Neurol 17(1): 49-54.

Sidhu, A., C. Wersinger, et al. (2004). "alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease." FEBS Lett 565(1-3): 1-5.

Sidhu, A., C. Wersinger, et al. (2004). "Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?" Faseb J 18(6): 637-47.

Small, G. W. (2004). "Neuroimaging as a diagnostic tool in dementia with Lewy bodies." Dement Geriatr Cogn Disord 17 Suppl 1: 25-31.

Sohn, Y. H. and M. Hallett (2004). "Motor evoked potentials." Phys Med Rehabil Clin N Am 15(1): 117-31, vii.

Stacy, M. (2004). "Apomorphine: North American clinical experience." Neurology 62(6 Suppl 4): S18-21.

Steele, P. E., P. H. Tang, et al. (2004). "Clinical laboratory monitoring of coenzyme Q10 use in neurologic and muscular diseases." Am J Clin Pathol 121 Suppl: S113-20.

Stewart, D., E. Morgan, et al. (2004). "Dopamine agonist switching in Parkinson's disease." Hosp Med 65(4): 215-9.

Stieglitz, T., M. Schuettler, et al. (2004). "Neural prostheses in clinical applications--trends from precision mechanics towards biomedical microsystems in neurological rehabilitation." Biomed Tech (Berl) 49(4): 72-7.

Stocchi, F. and C. W. Olanow (2004). "Continuous dopaminergic stimulation in early and advanced Parkinson's disease." Neurology 62(1 Suppl 1): S56-63.

Strickland, D. and J. M. Bertoni (2004). "Parkinson's prevalence estimated by a state registry." Mov Disord 19(3): 318-23.

Swope, D. M. (2004). "Rapid treatment of "wearing off" in Parkinson's disease." Neurology 62(6 Suppl 4): S27-31.

Takuma, K., A. Baba, et al. (2004). "Astrocyte apoptosis: implications for neuroprotection." Prog Neurobiol 72(2): 111-27.

Tambur, A. R. (2004). "Transplantation immunology and the central nervous system." Neurol Res 26(3): 243-55.

Tanaka, K. and N. Ogawa (2004). "Possibility of non-immunosuppressive immunophilin ligands as potential therapeutic agents for Parkinson's disease." Curr Pharm Des 10(6): 669-77.

Tapia-Nunez, J. and P. Chana-Cuevas (2004). "[Diagnosis of Parkinson's disease]." Rev Neurol 38(1): 61-7.

Thomas, M. and W. D. Le (2004). "Minocycline: neuroprotective mechanisms in Parkinson's disease." Curr Pharm Des 10(6): 679-86.

Thomas, S. (2004). "The role of health professionals in supporting expert patients schemes." Prof Nurse 19(8): 442-5.

Thomas, S. and D. MacMahon (2004). "Parkinson's disease, palliative care and older people: Part 2." Nurs Older People 16(2): 22-6; quiz 28.

Thomas, S. and D. MacMahon (2004). "Parkinson's disease, palliative care and older people: Part 1." Nurs Older People 16(1): 22-6.

Thorpy, M. J. (2004). "Sleep disorders in Parkinson's disease." Clin Cornerstone 6 Suppl 1A: S7-15.

Tinsley, R. and P. Eriksson (2004). "Use of gene therapy in central nervous system repair." Acta Neurol Scand 109(1): 1-8.

Toft, M. and J. Aasly (2004). "[The genetics of Parkinson disease]." Tidsskr Nor Laegeforen 124(7): 922-4.

Tretter, L., I. Sipos, et al. (2004). "Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease." Neurochem Res 29(3): 569-77.

Trzesniewska, K., M. Brzyska, et al. (2004). "Neurodegenerative aspects of protein aggregation." Acta Neurobiol Exp (Wars) 64(1): 41-52.

Vermel, A. E. (2004). "[Stem cells: general characteristics and perspectives of their clinical use]." Klin Med (Mosk) 82(1): 5-11.

Vila, M. and S. Przedborski (2004). "Genetic clues to the pathogenesis of Parkinson's disease." Nat Med 10 Suppl: S58-62.

Volkmann, J. (2004). "Deep brain stimulation for the treatment of Parkinson's disease." J Clin Neurophysiol 21(1): 6-17.

Wang, L. H., C. G. Besirli, et al. (2004). "Mixed-lineage kinases: a target for the prevention of neurodegeneration." Annu Rev Pharmacol Toxicol 44: 451-74.

West, A. B. and N. T. Maidment (2004). "Genetics of parkin-linked disease." Hum Genet 114(4): 327-36.

Willis, G. L. and G. A. Kennedy (2004). "The implementation of acute versus chronic animal models for treatment discovery in Parkinson's disease." Rev Neurosci 15(1): 75-87.

Wu, G., Y. Z. Fang, et al. (2004). "Glutathione metabolism and its implications for health." J Nutr 134(3): 489-92.

Xu, X., S. Pin, et al. (2004). "Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis." Ann N Y Acad Sci 1012: 299-305.

Yamada, M. and H. Yasuhara (2004). "Clinical pharmacology of MAO inhibitors: safety and future." Neurotoxicology 25(1-2): 215-21.

Zhu, B. T. (2004). "CNS dopamine oxidation and catechol-O-methyltransferase: importance in the etiology, pharmacotherapy, and dietary prevention of Parkinson's disease." Int J Mol Med 13(3): 343-53.

Back to top

 Last Updated: April 2008 | Disclaimer